When you're in the innovation business, you take some risks and temper your expectations. When one of your innovations produces $100 million in annual savings, you know you're doing something right.
WHEN YOU'RE IN THE INNOVATION business, you take some risks and temper your expectations. When one of your innovations produces $100 million in annual savings, you know you're doing something right.
For global tech giant IBM, innovations to save healthcare dollars among the 340,000 people enrolled in its benefit plan fall squarely on the shoulders of Martin Sepulveda, MD, vice president of global well-being services and health benefits. Dr. Sepulveda, an approachable, easy-going executive, doesn't seem the type to brag about saving the self-insured corporation $100 million on its healthcare bill or about the fact that employees never pay a dime in premiums, but deep down, he probably knows that other employers would love to know his secret.
Health benefits are usually the biggest non-cash portion of employee compensation. Higher-paid workers tend to prefer health benefits, while lower-income workers often prefer to have more money in their paychecks instead of generous health benefits, says Devon Herrick, senior fellow, National Center for Policy Analysis (NCPA), Dallas.
"Employees often do not even know what their health plan is costing," NCPA's Herrick says. "Also, getting to the point where employers understand the amount of cash wages that workers are willing to forgo for a variety of different benefit levels can be hard to ascertain."
Herrick believes that, hypothetically, if IBM were to stop offering health benefits altogether, most if not all of the employees would probably be willing to stay with the company if they were offered higher salaries to compensate for the lost health coverage. With an optimal mix of cash and non-cash compensation, companies can attract and retain a skilled workforce, but a mix that works for one company or one industry might not work for another, he says.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More